Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Oncopeptides AB ( (SE:ONCO) ).
Oncopeptides has secured regulatory and ethics approval in Norway to initiate its Window-of-Opportunity clinical study in glioblastoma, clearing the way for patient recruitment to begin sooner than the company anticipated. The study will enroll around 10 patients and represents the first clinical evaluation of a Peptide Drug Conjugate in glioblastoma, aiming to demonstrate that the firm’s technology can penetrate the human blood-brain barrier and thus support development of its next-generation candidate OPD5.
The authorization marks a significant operational milestone in Oncopeptides’ strategy to extend its PDC platform beyond multiple myeloma and deepen its presence in highly underserved oncology indications. Management highlights the fast-track review and swift approval as evidence of strong alignment with Scandinavian regulators, a factor that could accelerate clinical data generation and potentially enhance the company’s competitive positioning in the neuro-oncology space.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotechnology company developing targeted therapies for difficult-to-treat cancers, leveraging its proprietary Peptide Drug Conjugate and SPiKE technology platforms to deliver cytotoxic agents selectively into cancer cells. The company’s flagship drug is being commercialized in Europe, supported by partnerships in South Korea, the Middle East, Africa and other territories, and it employs about 80 staff across operations in Sweden, Germany, Austria, Spain and Italy while being listed on Nasdaq Stockholm under the ticker ONCO.
Average Trading Volume: 4,374,217
Technical Sentiment Signal: Sell
Current Market Cap: SEK655.1M
For an in-depth examination of ONCO stock, go to TipRanks’ Overview page.